NDAORALTABLET
Approved
Jan 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HIWOLFIA is an oral tablet formulation of Rauwolfia serpentina root, a natural alkaloid extract approved in 1954. The mechanism of action and specific indications are not documented in current data, reflecting its age and legacy status as an early NDA product. This botanical extract represents a historical class of antihypertensive agents largely superseded by modern therapeutics.
LOE Approaching
Minimal commercial activity expected; small brand team likely focused on legacy portfolio maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked jobs indicate minimal active hiring for this product line. Career opportunities are confined to legacy portfolio stewardship, regulatory filing maintenance, and compliance monitoring rather than commercial growth or innovation roles.
Regulatory Affairs SpecialistPortfolio Manager
Worked on HIWOLFIA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.